|
CALGB 30610
Stage III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
INVESTIGATOR: Vijay Kasturi, MD
SPONSOR: Cancer and Leukemia Group B
CALGB 30610 at clinicaltrials.gov
CALGB 140503
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2cm) Peripheral Non-Small Cell Lung Cancer
INVESTIGATOR: Karl Fabian Uy, MD
SPONSOR: CALGB (Cancer and Leukemia Group B)
CALGB 140503 at clinicaltrials.gov
ECOG 1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>/= 4cm) - IIIA Non-Small-Cell Lung Cancer (NSCLC)
INVESTIGATOR: William Walsh, MD
SPONSOR: Eastern Cooperative Oncology Group
ECOG 1505 at clinicaltrials.gov
ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non Squamous NSCLC
INVESTIGATOR: William Walsh, MD
SPONSOR: NCI/Eastern Cooperative Oncology Group
ECOG 5508 at clinicaltrials.gov
Montefiore (UM200703)
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) versus Single Agent Pemetrexed (Alimta) in Patients with Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC)
INVESTIGATOR: William Walsh, MD
SPONSOR: Montefiore Medical Center
Montefiore at clinicaltrials.gov
GSK MAGRIT
A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of rec MAGE-A3 + AS15 Antigen-Specific Cancer Immunotherpeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer
INVESTIGATOR: Syed Quadri, MD
SPONSOR: GlaxoSmithKline Pharmaceutical
GSK MAG RIT at clinicaltrials.gov
|